PCI — other cancer indications
This thread is to discuss and gather intel on pci potential in other cancer indications, we ll start with the following:
Soft tissue sarcoma
This is a 2017 publication for pci in sarcoma indication, Kristian Berg is a co-writer.
Conclusion:
The results indicate PCIBLM as a potential novel treatment strategy for soft tissue sarcomas, with antioxidant enzymes, in particular GPx1, and the P53 status as potential predictive markers for response to PCIBLM.
https://www.ncbi.nlm.nih.gov/m/pubmed/28838761/
About Sarcoma:
https://www.cancer.org/cancer/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html
Soft tissue sarcoma
This is a 2017 publication for pci in sarcoma indication, Kristian Berg is a co-writer.
Conclusion:
The results indicate PCIBLM as a potential novel treatment strategy for soft tissue sarcomas, with antioxidant enzymes, in particular GPx1, and the P53 status as potential predictive markers for response to PCIBLM.
https://www.ncbi.nlm.nih.gov/m/pubmed/28838761/
About Sarcoma:
https://www.cancer.org/cancer/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html
Redigert 17.08.2018 kl 23:23
Du må logge inn for å svare
Stock DZ
17.08.2018 kl 23:21
2030
Ovarian cancer
This was presented in ASPIC world congress 10-11 May/2018.
Page 76
https://3rdcongress.aspic.pt/sites/default/files/proceedins_book_3rd_congress_aspic.pdf
Results and Discussion: PCI lead to a synergistic effect when using 1nM and 2nM dactinomycin compared to using PDT or dactinomycin alone with the PCI effect being slightly higher using 2nM dactinomycin compared to 1nM. For cells that were illuminated for 5 minutes PCI produced 3.1 fold higher efficacy in cell kill vs. PDT (p< 0.001) using 1nM dactinomycin and 4.4 fold higher efficacy vs. PDT (p<0.001) using 2nM dactinomycin in HEY cells. The same conditions produced 1.9 (1nM) and 3.1 (2nM) fold higher efficacy vs. PDT (p<0.001) in SKOV3 cells. These results have indicated that the compressed 3D cancer model is promising way to study PCI as well as demonstrating the potential of PCI as a minimally invasive method for treating ovarian cancer in the future. The significant difference between PCI and PDT results shows the synergistic effect produced with the combination of both TPPS2a and dactinomycin.
This was presented in ASPIC world congress 10-11 May/2018.
Page 76
https://3rdcongress.aspic.pt/sites/default/files/proceedins_book_3rd_congress_aspic.pdf
Results and Discussion: PCI lead to a synergistic effect when using 1nM and 2nM dactinomycin compared to using PDT or dactinomycin alone with the PCI effect being slightly higher using 2nM dactinomycin compared to 1nM. For cells that were illuminated for 5 minutes PCI produced 3.1 fold higher efficacy in cell kill vs. PDT (p< 0.001) using 1nM dactinomycin and 4.4 fold higher efficacy vs. PDT (p<0.001) using 2nM dactinomycin in HEY cells. The same conditions produced 1.9 (1nM) and 3.1 (2nM) fold higher efficacy vs. PDT (p<0.001) in SKOV3 cells. These results have indicated that the compressed 3D cancer model is promising way to study PCI as well as demonstrating the potential of PCI as a minimally invasive method for treating ovarian cancer in the future. The significant difference between PCI and PDT results shows the synergistic effect produced with the combination of both TPPS2a and dactinomycin.
Stock DZ
18.08.2018 kl 00:09
1962
Lung cancer
This is based on the following patent application
https://patents.google.com/patent/US20110293575
Quote:
In summary these results show that PCI can significantly potentiate the cytotoxic effect of both the Tyrosine Kinase Inhibitors erlotinib and nilotinib. The potentiation effect was most prominent for erlotinib, with a 10 times potentiation observed in the lung cancer cell line NCI-H460 and at least a 20 times potentiation seen in the multi-drug resistant cell line NCI-ADR-RES. For nilotinib the corresponding potentiation factors were 3.5 and 2, respectively. In most experiments the PCI-induced potentiation was observed under conditions where the photochemical treatment in itself did not have any cytotoxic effect, indicating a strong synergistic effect. The fact that PCI gives strong enhancement also on drug resistant cells indicates that PCI can be used to treat also tumours that are drug resistant, something that may be very important in a clinical situation.
This is based on the following patent application
https://patents.google.com/patent/US20110293575
Quote:
In summary these results show that PCI can significantly potentiate the cytotoxic effect of both the Tyrosine Kinase Inhibitors erlotinib and nilotinib. The potentiation effect was most prominent for erlotinib, with a 10 times potentiation observed in the lung cancer cell line NCI-H460 and at least a 20 times potentiation seen in the multi-drug resistant cell line NCI-ADR-RES. For nilotinib the corresponding potentiation factors were 3.5 and 2, respectively. In most experiments the PCI-induced potentiation was observed under conditions where the photochemical treatment in itself did not have any cytotoxic effect, indicating a strong synergistic effect. The fact that PCI gives strong enhancement also on drug resistant cells indicates that PCI can be used to treat also tumours that are drug resistant, something that may be very important in a clinical situation.
Redigert 18.08.2018 kl 00:10
Du må logge inn for å svare
Stock DZ
18.08.2018 kl 00:57
1910
Prostate cancer
I found this full PhD thesis from UCL (university college London) from 2016 titled: Light-based therapies in Prostate Cancer treatment
It has both in vitro and in vivo studies for prostate cancer (using PCI and PDT) and also a whole chapter (chapter-5) on Stimulation of the immune system following PDT and PCI in Prostate Cancer.
http://discovery.ucl.ac.uk/1532467/1/Martinez%20de%20Pinillos%20Bayona_A_e-THESIS%2018.12.16.pdf
I found this full PhD thesis from UCL (university college London) from 2016 titled: Light-based therapies in Prostate Cancer treatment
It has both in vitro and in vivo studies for prostate cancer (using PCI and PDT) and also a whole chapter (chapter-5) on Stimulation of the immune system following PDT and PCI in Prostate Cancer.
http://discovery.ucl.ac.uk/1532467/1/Martinez%20de%20Pinillos%20Bayona_A_e-THESIS%2018.12.16.pdf
Redigert 18.08.2018 kl 00:59
Du må logge inn for å svare
fabian2
18.08.2018 kl 02:46
1865
Gracias a Usted....du er jo et skikkelig funn for gravevirksomhet…..antar du skjønner norsk , selv om du skriver på engelsk ?